Bafna Pharmaceutical
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Dec 8 (Reuters) - Bafna Pharmaceuticals Ltd BAFP.NS:
COMMERCIAL PRODUCTION AT CO'S MANUFACTURING FACILITIES IN CHENNAI, TAMIL NADU STARTED
DUE TO IMPACT OF “MICHAUNG” CYCLONE CO'S MANUFACTURING FACILITIES IN CHENNAI, TAMIL NADU WAS FLOODED/ WATERLOGGED
PRODUCTION ACTIVITIES WERE DISRUPTED FROM DEC. 04, 2023
Source text for Eikon: ID:nBSE9cMkWj
Further company coverage: BAFP.NS
(([email protected];))
Dec 8 (Reuters) - Bafna Pharmaceuticals Ltd BAFP.NS:
COMMERCIAL PRODUCTION AT CO'S MANUFACTURING FACILITIES IN CHENNAI, TAMIL NADU STARTED
DUE TO IMPACT OF “MICHAUNG” CYCLONE CO'S MANUFACTURING FACILITIES IN CHENNAI, TAMIL NADU WAS FLOODED/ WATERLOGGED
PRODUCTION ACTIVITIES WERE DISRUPTED FROM DEC. 04, 2023
Source text for Eikon: ID:nBSE9cMkWj
Further company coverage: BAFP.NS
(([email protected];))
Dec 7 (Reuters) - Bafna Pharmaceuticals Ltd BAFP.NS:
DUE TO TORRENTIAL RAINSOF MICHAUNG CYCLONE, CO'S MANUFACTURING FACILITIES IN CHENNAI WAS TOTALLY FLOODED
PRODUCTION ACTIVITIES HAVE BEEN DISRUPTED FROM DEC 4
Source text for Eikon: ID:nBSE8DxK5X
Further company coverage: BAFP.NS
(([email protected];))
Dec 7 (Reuters) - Bafna Pharmaceuticals Ltd BAFP.NS:
DUE TO TORRENTIAL RAINSOF MICHAUNG CYCLONE, CO'S MANUFACTURING FACILITIES IN CHENNAI WAS TOTALLY FLOODED
PRODUCTION ACTIVITIES HAVE BEEN DISRUPTED FROM DEC 4
Source text for Eikon: ID:nBSE8DxK5X
Further company coverage: BAFP.NS
(([email protected];))
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Bafna Pharmaceutical do?
Bafna Pharmaceuticals Ltd specializes in manufacturing tablets, capsules, and oral syrups, focusing on prescription drugs for the global market. They offer contract manufacturing services and a wide range of pharmaceutical categories.
Who are the competitors of Bafna Pharmaceutical?
Bafna Pharmaceutical major competitors are Haleos Labs, Albert David, Aptus Pharma, Jenburkt Pharma, Valiant Laboratories, Kappac Pharma, Medico Remedies. Market Cap of Bafna Pharmaceutical is ₹447 Crs. While the median market cap of its peers are ₹403 Crs.
Is Bafna Pharmaceutical financially stable compared to its competitors?
Bafna Pharmaceutical seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Bafna Pharmaceutical pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Bafna Pharmaceutical latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Bafna Pharmaceutical allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments
How strong is Bafna Pharmaceutical balance sheet?
Balance sheet of Bafna Pharmaceutical is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Bafna Pharmaceutical improving?
The profit is oscillating. The profit of Bafna Pharmaceutical is ₹11.1 Crs for TTM, ₹4.15 Crs for Mar 2025 and ₹7.35 Crs for Mar 2024.
Is the debt of Bafna Pharmaceutical increasing or decreasing?
The net debt of Bafna Pharmaceutical is decreasing. Latest net debt of Bafna Pharmaceutical is ₹21.34 Crs as of Mar-25. This is less than Mar-24 when it was ₹21.6 Crs.
Is Bafna Pharmaceutical stock expensive?
Bafna Pharmaceutical is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Bafna Pharmaceutical is 42.3, while 3 year average PE is 94.79. Also latest EV/EBITDA of Bafna Pharmaceutical is 29.13 while 3yr average is 24.26.
Has the share price of Bafna Pharmaceutical grown faster than its competition?
Bafna Pharmaceutical has given better returns compared to its competitors. Bafna Pharmaceutical has grown at ~39.03% over the last 2yrs while peers have grown at a median rate of 6.0%
Is the promoter bullish about Bafna Pharmaceutical?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Bafna Pharmaceutical is 75.0% and last quarter promoter holding is 75.0%.
Are mutual funds buying/selling Bafna Pharmaceutical?
There is Insufficient data to gauge this.